Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.

@article{Chen2009ClopidogrelIC,
  title={Clopidogrel inhibits CYP2C19-dependent hydroxylation of omeprazole related to CYP2C19 genetic polymorphisms.},
  author={Bi-Lian Chen and Yao Chen and Jui Hung Tu and You Lan Li and Wei Zhang and Qing Li and Lan Fan and Z R Tan and David L Hu and Dan Wang and Lian-Sheng Wang and Dong-sheng Ouyang and Hong-Hao Zhou},
  journal={Journal of clinical pharmacology},
  year={2009},
  volume={49 5},
  pages={574-81}
}
This study explores the impact of clopidogrel on the pharmacokinetics of omeprazole related to CYP2C19 genetic polymorphisms. Twelve healthy volunteers (6 CYP2C19*1/*1, 5 CYP2C19*2/*2, and 1 CYP2C19*2/*3) are enrolled in a 2-phase randomized crossover trial. In each phase, the volunteers are administered a single oral dose of omeprazole 40 mg after pretreatment of either placebo or clopidogrel (300 mg on the first day and then 75 mg once daily for 3 consecutive days). Plasma concentrations of… CONTINUE READING